Stop FDA Approval of Pfizer Shots for Kids 6 Months to 4 Years on February 15

by Toby Rogers, PhD

UPDATE: The clinical trial failed in this age group. We have 5 days to stop the U.S. Food and Drug Administration from committing a crime against humanity. Comments received on or before February 10, 2022, will be provided to the committee.

Please submit formal comments to the FDA

Take Action

Sample Letters to FDA.

The FDA has now opened up formal comment in connection with the Feb. 15 VRBPAC meeting:

FDA has established a docket for public comment on this meeting. The docket number is FDA-2022-N-0082.  The docket will close on February 14, 2022. Submit either electronic or written comments on this public meeting by February 14, 2022. Please note that late, untimely filed comments will not be considered. The https://www.regulations.govelectronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of February 14, 2022. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

Most of you will probably want to submit electronically here:

https://www.regulations.gov/search?filter=fda-2022-n-0082

Select Category: Individual Consumer or Health Professional

A few sentences is fine. Simply explain why the FDA must vote NO. I like:

1. There is no emergency in this age group that would justify this use;
2. The clinical trial of the Pfizer vaccine failed in this age group; and
3. You must vote NO because this proposed use violates the prohibitions against illegal medical experiments as outlined in the Nuremberg Code.

Mail/Hand delivery/Courier (for written/paper submissions) would need to go out immediately (Feb. 8 or Feb. 9):
Dockets Management Staff (HFA-305),
Food and Drug Administration,
5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852

Pfizer announcement wants their disastrous mRNA shot added to the official schedule for children so that they can have liability protection forever.

The Pfizer mRNA shot in children 2- to 4-years old failed in the clinical trial.

Acting FDA Commissioner, Janet Woodcock, following orders from the Biden administration said, (I’m paraphrasing here) ‘don’t worry about the fact that the shot does not work, we’ve got a drug to sell, submit an Emergency Use Authorization (EUA) application anyway.’

So Tuesday (Feb. 1) Pfizer submitted an EUA application for children six-months to four-years old.

Pfizer and the FDA are proposing to start with two shots in this age group even though that approach has already failed and then they will add a third dose later in the spring if data comes in that supports that use. The plan is literally — shoot up kids first, get the data later. This approach is completely unprecedented in the history of the FDA and it must be stopped.

The FDA’s Vaccines and Related Biological Products Advisory Committee will meet in two weeks — on February 15 — to evaluate this EUA application for a product that failed the clinical trial.

YOUR ACTION IS NEEDED!!!

So warriors, you know what to do. I need you to get on the phone, get your fax machines humming, and start sending out emails like the future of this country depends on it — because it does. Physical paper letters sent in the next couple days via the U.S. Postal Service will probably get there in time too.

In October we generated tens of thousands of calls, emails, and faxes. Our goal in the next two weeks must be to generate hundreds of thousands of calls, emails, faxes, and letters.

The message we need to send to these bureaucrats is — ABSOLUTELY NOT! Every single person who plays a role in this decision needs to get the message that:

1. We are watching;
2. The clinical trial of the Pfizer vaccine failed in this age group; and
3. You must vote NO because this proposed use violates the prohibitions against illegal medical experiments as outlined in the Nuremberg Code.

Anyone who goes along with Janet Woodcock’s bullying on behalf of the cartel will be prosecuted for crimes against humanity.

It’s hard to know exactly who will be at the VRBPAC meeting because the FDA uses Temporary Voting Members and the VRBPAC has not met since we exposed them as frauds back in October (when they rubber stamped Pfizer’s EUA application for kids 5 to 11 in spite of no data showing clinical effectiveness). But the best guess is that the voting members will be roughly the same as the last meeting so that is who we are reaching out to now.

Here are the 23 people we need to reach before Tuesday, February 15:

Janet Woodcock
Acting FDA Commissioner
FDA, mail stop: HFD-001
10903 New Hampshire Ave., WO51-6133
Silver Spring MD 20993-0002
phone: (301) 796-5400
fax: (301) 847-8752
Janet.Woodcock@fda.hhs.gov
https://twitter.com/DrWoodcockFDA

Rochelle Walensky
Director, Centers for Disease Control and Prevention
Roybal Building 21, Rm 12000
1600 Clifton Rd
Atlanta, GA 30333
phone: (404) 639-7000
Aux7@cdc.gov
https://twitter.com/CDCDirector

Xavier Becerra
Secretary, Health & Human Services
200 Independence Avenue S.W.
Washington, D.C. 20201
c/o Sean McCluskie
sean.mccluskie@hhs.gov
https://twitter.com/XavierBecerra

Peter Marks
Director, Center for Biologics Evaluation and Research
FDA, Mail stop: HFM-2
10903 New Hampshire Ave., WO71-7232
Silver Spring MD 20993-0002
phone: (240) 402-8116
fax: (301) 595-1310
Peter.Marks@fda.hhs.gov

Acting Chair, VRBPAC
Arnold Monto, M.D.
Professor of Public Health & Epidemiology
Department of Epidemiology
University of Michigan School of Public Health
Ann Arbor, MI 48109
phone: (734) 764-5453
fax: (734) 764-3192
asmonto@umich.edu

Paula Annunziato, M.D.
Vice President and Therapeutic Area Head
Vaccines Clinical Research
Merck
North Wales, PA 19454
paula.annunziato@merck.com

Captain Amanda Cohn
Chief Medical Officer
National Center for Immunizations and Respiratory Diseases
Centers for Disease Control and Prevention
1600 Clifton Rd
Atlanta, GA 30333 MS C-09
phone: (404) 639-6039
fax: (404) 315-4679
acohn@cdc.gov
anc0@cdc.gov

Hayley Gans, M.D.
Professor of Pediatrics
Department of Pediatrics
Stanford University Medical Center
Stanford, CA 94305
phone: (650) 723-5682
fax: (650) 725-8040
hgans@stanford.edu

Michael Kurilla, M.D., Ph.D.
Director, Division of Clinical Innovation
National Center for Advancing Translation Sciences
National Institutes of Health
Bethesda, MD 20852
phone: (301) 435-0178
Michael.kurilla@nih.gov

H. Cody Meissner, M.D.
Professor of Pediatrics
Tufts University School of Medicine
Director, Pediatric Infectious Disease
Tufts Medical Center
Boston, MA 02111
phone: (617) 636-5227
fax: (617) 636-4300
cmeissner@tuftsmedicalcenter.org

Paul Offit, M.D.
Professor of Pediatrics
Division of Infectious Diseases
Abramson Research Building
The Children’s Hospital of Philadelphia
Philadelphia, PA 19104
phone: (215) 590-2020
offit@chop.edu
https://twitter.com/DrPaulOffit

Steven Pergam, M.D.
Medical Director
Infection Prevention
Seattle Cancer Care Alliance
Seattle, WA 98109
phone: (206) 667-7126
spergam@fredhutch.org
https://twitter.com/PergamIC

Temporary Voting Members (but their votes count all the same)

A. Oveta Fuller, Ph.D.
Associate Professor of Microbiology and Immunology,
University of Michigan Medical School
Ann Arbor, MI 48109
phone: (734) 647-3830
fullerao@umich.edu

James Hildreth, Sr., Ph.D., M.D.
Professor
Department of Internal Medicine
School of Medicine
President and Chief Executive Officer
Meharry Medical College
Nashville, TN 37205
officeofthepresident@mmc.edu
https://twitter.com/JamesEKHildreth

Jeannette Lee, Ph.D.
Professor Department of Biostatistics
University of Arkansas for Medical Sciences
Little Rock, AR 72701
phone: (501) 526-6712
JYLee@uams.edu 

Ofer Levy, M.D., Ph.D.
Staff Physician & Principal Investigator
Director, Precision Vaccines Program
Division of Infectious Diseases
Boston Children’s Hospital
Harvard Medical School Associate Member
phone: (617) 919-2900
fax: (617) 730-0254
ofer.levy@childrens.harvard.edu
https://twitter.com/levy_o

Patrick Moore, M.D., M.P.H.
Distinguished and American Cancer Society Professor
Pittsburgh Foundation Chair in Innovative Cancer Research
University of Pittsburgh Cancer Institute
Pittsburgh, PA 15213
phone: (412) 623-7721
psm9@pitt.edu

Michael Nelson, M.D., Ph.D.
Professor of Medicine 
Asthma, Allergy and Immunology Division
UVA Division of Asthma, Allergy & Immunology
PO Box 801355
Charlottesville, VA 22908
phone: (434) 297-8399
fax: (434) 924-5779
mrn8d@virginia.edu

Stanley Perlman, M.D., Ph.D.
Professor of Pediatrics
University of Iowa
3-712 Bowen Science Building (BSB)
51 Newton Rd
Iowa City, IA 52242
phone: (319) 335-8549
stanley-perlman@uiowa.edu

Jay Portnoy, M.D.
Director,
Division of Allergy, Asthma & Immunology
Children’s Mercy Hospitals & Clinics
2401 Gillham Road Kansas City, MO 64108
phone: (816) 960-8885
fax: (816) 960-8888
Jportnoy@cmh.edu

Eric Rubin, M.D., Ph.D.
Editor-in-Chief
New England Journal of Medicine
Adjunct Professor
Harvard TH Chan School of Public Health
665 Huntington Ave
Building 1, Room 811
Boston, MA  02115
phone: (617) 432-3335
erubin@hsph.harvard.edu
erubin@nejm.org

Mark Sawyer, M.D.
Professor of Clinical Pediatrics
8110 Birmingham Way
Bldg. 28, 1st Floor
San Diego, CA 92123
phone: (858) 966-7785
fax: (858) 966-8658
mhsawyer@health.ucsd.edu

Melinda Wharton, M.D., MPH
Associate Director for Vaccine Policy
National Center for Immunization and Respiratory Diseases,
Centers for Disease Control and Prevention,
1600 Clifton Road, Mailstop E05,
Atlanta, GA 30333
phone: (404) 639.8755
fax: (404) 639.8626
mew2@cdc.gov

Please be respectful and courteous. Let’s do this! 🙌

Subscribe to Toby Rogers, PhD.

Donate to PERK